About Lipocine
Lipocine is a publicly listed company based in Salt Lake City (United States) founded in 1997. Oral hormones are developed via Hydroance delivery technology. The company has 16 employees. Lipocine offers products and services including TLANDO, LPCN 1144, LPCN 1154, LPCN 1148, and LPCN 1107. Its focus areas include Life Sciences, Drug Delivery, Oral and Metabolic Diseases. Its legal entity is LIPOCINE INC. Similar companies include Neurocrine, Crinetics and Lyndra; 3 of its 3 listed similar companies have raised funding.
Company details
Lipocine is a specialty pharmaceutical company that develops oral versions of hormones based on Hydroance, a drug delivery technology. Product pipelines are LPCN 1021, an oral testosterone replacement product (Phase 3); LPCN 1111 which is an oral testosterone candidate (Phase 2); and LPCN 1107, an oral hydroxyprogesterone caproate product candidate for the prevention of recurrent preterm birth (Phase 1). The company also develops respiratory products for cough and cold conditions. The company uses the lipid-based technology platform for non-invasive delivery solutions for small polar organics and macromolecules. The company went public in 2013.
- Headquarters Salt Lake City, United States
- Employees 16
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website lipocine.com
- Social LinkedIn
- Legal Name Lipocine Inc.
- Annual Revenue$1.98 M (USD)-82.35as on Dec 31, 2025
- Net Profit-$9.63 M (USD)-115371.85as on Dec 31, 2025
- EBITDA-$10.31 M (USD)-825.61as on Dec 31, 2025
- Latest Funding Round$38.02M (USD), Post-IPO
Aug 2013
- Employee Count16
Products & Services of Lipocine
Lipocine offers a comprehensive portfolio of products and services, including TLANDO, LPCN 1144, LPCN 1154, LPCN 1148, and LPCN 1107.
FDA-approved oral therapy for restoring testosterone levels in males.
Oral prodrug for non-cirrhotic non-alcoholic steatohepatitis management.
Oral neuro-steroid for treating postpartum depression symptoms.
Oral prodrug for symptoms associated with liver cirrhosis.
Oral candidate to prevent recurrent preterm births in women.
Funding Insights of Lipocine
- Total Rounds 1
- Last Round Post-IPO — $38.02M
- First Round $38.02M
(Aug 2013)
All 1 funding rounds of Lipocine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2013 | $38.02M | Post-IPO | – | – | – |
People of Lipocine
10 people are tracked at Lipocine (4 in leadership, 6 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Anthony Delconte | Chief Medical Director | Leadership |
Mahesh V. Patel | Chairman, President & CEO | Leadership |
Ben Bruno | Vice President Clinical Research | Leadership |
Samuel Akapo | Senior Director, Chemistry, Manufacturing and Control (CMC) | Leadership |
Chidu (Nachiappan) Chidambaram | SVP | Team |
Stephanie Sorensen | Assistant Controller | Team |
Kongnara Papangkorn | Business Development Manager | Team |
Krista Fogarty | Corporate Controller | Team |
Jonathan Ogle | Senior Scientist | Team |
Joel Frank | Manager laboratory operations | Team |
Complete people profiles for Lipocine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lipocine
Lipocine is a publicly listed company on the NASDAQ with ticker symbol LPCN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Oct 2013
- Listed onNASDAQ: LPCN
- Listed entityLipocine Inc.
- Exchange sectorHealth technology
- ISINUS53630X2036
- Share price$1.62 (-2.41% on the day) · 2026-10-13
- Market capitalisation$13.4M
- EPS (diluted, trailing year)$-1.86
- Volume (last session)501,618
Financials of Lipocine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.0M | -$9.6M | -$10.3M |
| 2024 | $11.2M | $8,350 | -$1.1M |
| 2023 | $109,990 | -$16.4M | -$14.9M |
| 2022 | $500,000 | -$10.8M | -$12.1M |
| 2021 | $16.1M | -$634,400 | $3.1M |
Detailed financial statements for Lipocine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lipocine
3 dated milestones of Lipocine across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Lipocine is founded.
- Funding First funding round of $38.0M.
- IPO Lists on the stock exchange (IPO).
Similar companies to Lipocine
Lipocine has 3 listed similar companies in our database, 3 of them funded. They include Neurocrine, Crinetics and Lyndra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| crinetics.com | 2008 | San Diego, United States | $103.5M | 120 | Developer of therapies for the treatment of endocrine-related diseases and cancers | |
| lyndra.com | 2015 | Cambridge, United States | $305.01M | 107 | Innovates long-acting oral therapies to simplify patient medication regimens. |
Detailed similar companies of Lipocine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lipocine
The website of Lipocine (lipocine.com) receives about 6.3K visits a month and ranks #6,488,338 among all websites worldwide, #6,602 in Biotechnology and Pharmaceuticals.
- Monthly visits6.3K
▲ 136.6% vs previous month
- Unique visitors1.1K
per month
- Global rank#6,488,338
among all websites
- Category rank#6,602
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.5
- Average visit28 sec
- DevicesDesktop 25% · Mobile 75%
Websites whose visitors overlap most with Lipocine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| porwal.net | 100% | 1.1K | #14,642,220 | View details | |
| medreich.com | 99% | 1.9K | #7,047,446 | View details | |
| fiercebiotech.com | 78% | 858.3K | #81,022 | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Lipocine (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lipocine
Complete news archive for Lipocine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lipocine
Lipocine was founded in 1997 and raised its 1st funding round 16 years after it was founded.
Lipocine is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Lipocine has 16 employees.
Annual revenue of Lipocine is $1.98M as on Dec 31, 2025.
Lipocine is a specialty pharmaceutical company that develops oral versions of hormones based on Hydroance, a drug delivery technology. Product pipelines are LPCN 1021, an oral testosterone replacement product (Phase 3); LPCN 1111 which is an oral testosterone candidate (Phase 2); and LPCN 1107, an oral hydroxyprogesterone caproate product candidate for the prevention of recurrent preterm birth (Phase 1). The company also develops respiratory products for cough and cold conditions. The company uses the lipid-based technology platform for non-invasive delivery solutions for small polar organics and macromolecules. The company went public in 2013.
Lipocine's top competitors include Crinetics, Neurocrine and Lyndra.
Lipocine offers TLANDO, LPCN 1144, LPCN 1154, LPCN 1148, and LPCN 1107.
Yes, Lipocine is publicly traded on NASDAQ under the ticker symbol LPCN.
Lipocine operates through Lipocine Inc..